| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CCO | CCO & EVP, Bus. Development
1 company
Joshua Schafer is CCO at ZVRA. Joshua Schafer's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $639K at current prices.
Historically, Joshua Schafer's trades have earned a middling insider score of 53/100 across 6 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +13.8%.
The ZVRA filings lean toward selling, a net 20,875 shares.
Joshua Schafer has 9 Form 4 filings on record from January 2023 to February 2026, all as CCO at Zevra Therapeutics (ZVRA), 2023–2026.
The 15 reported transactions were 6 option or other derivative awards, 3 open-market sales, 3 option exercises and 3 open-market purchases.
Counted by filing, the open-market trades come to 3 purchases worth about $17K and 3 sales worth about $209K.
The largest open-market purchase was 2,000 shares of ZVRA at an average $4.61 on March 14, 2023, about $9K. Twelve months later ZVRA was up 31%.
The largest open-market sale was 10,500 shares of ZVRA at an average $9.19 on February 3, 2026, about $97K.
All 3 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | ZVRA Zevra Therapeutics, Inc. | CCO | Sell10b5-1 | 10,500 | $9.19 | $96,500.25 | -14.4% | +9.7% | - | |
| Jan 30, 2026 | ZVRA Zevra Therapeutics, Inc. | CCO | Sale+OE10b5-1 | 3,375 | $8.83 | $29,800.24 | -8.3% | +13.0% | - | |
| Feb 13, 2025 | ZVRA Zevra Therapeutics, Inc. | CCO & EVP, Bus. Development | Sell10b5-1 | 10,500 | $7.86 | $82,526.85 | -26.3% | +1.9% | +6.4% | |
| Sep 5, 2023 | ZVRA Zevra Therapeutics, Inc. | CCO & EVP, Bus. Development | Buy | 500 | $5.13 | $2,564.50 | +16.7% | +0.8% | +42.9% | |
| May 19, 2023 | ZVRA Zevra Therapeutics, Inc. | CCO & EVP, Bus. Development | Buy | 1,000 | $5.42 | $5,415.70 | +50.0% | -8.5% | -12.4% | |
| Mar 14, 2023 | ZVRA Zevra Therapeutics, Inc. | CCO & EVP, Bus. Development | Buy | 2,000 | $4.61 | $9,217.80 | New | +16.3% | +31.1% |